# Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

> **NCT06106295** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 30 (estimated)

## Conditions studied

- Autonomous Cortisol Secretion
- Mild Autonomous Cortisol Secretion (MACS)

## Interventions

- **DRUG:** Metyrapone

## Key facts

- **NCT ID:** NCT06106295
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-19
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-02-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06106295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06106295, "Metyrapone for Mild Autonomous Cortisol Secretion (MACS)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06106295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*